Facebook Linkedin RSS Twitter Youtube
Home 2024

Recursion Pharmaceuticals

Recursion’s Ambitions: Developing 100+ Candidates, Joining with Exscientia
Artificial Intelligence

Recursion’s Ambitions: Developing 100+ Candidates, Joining with Exscientia

Recursion’s CEO Discusses Pipeline Growth, Approach to AI and ML
Artificial Intelligence

Recursion’s CEO Discusses Pipeline Growth, Approach to AI and ML

Recursion to Acquire Exscientia, Combining AI Drug Pioneers
Artificial Intelligence

Recursion to Acquire Exscientia, Combining AI Drug Pioneers

Recursion Completes Supercomputer for AI Drug Discovery
Artificial Intelligence

Recursion Completes Supercomputer for AI Drug Discovery

Restoring Hearing Loss, CAR T Manufacturing, DNA-Based Medicines, Nvidia and Recursion; Eric Topol
Artificial Intelligence

Restoring Hearing Loss, CAR T Manufacturing, DNA-Based Medicines, Nvidia and Recursion; Eric Topol

Drugs, Dollars, and Data: Recursion Eyes Cost Savings from AI Drug Discovery
Artificial Intelligence

Drugs, Dollars, and Data: Recursion Eyes Cost Savings from AI Drug Discovery

StockWatch: Nvidia Jumps 24% on Recursion, Amgen AI Partnerships
Artificial Intelligence

StockWatch: Nvidia Jumps 24% on Recursion, Amgen AI Partnerships

Ordaōs Uses AI to Generate Therapeutic Mini-Proteins
Artificial Intelligence

Ordaōs Uses AI to Generate Therapeutic Mini-Proteins

StockWatch: After $50M from Nvidia, Investors Bullish on Recursion
Artificial Intelligence

StockWatch: After $50M from Nvidia, Investors Bullish on Recursion

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.